The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
Adverse events were consistent with valbenazine’s established safety profile
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Subscribe To Our Newsletter & Stay Updated
